Xilio Therapeutics, Inc.
XLO
$0.71
-$0.03-4.44%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 31.80M | 15.00M | 9.27M | 6.34M | 4.62M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 31.80M | 15.00M | 9.27M | 6.34M | 4.62M |
| Cost of Revenue | 29.65M | 26.09M | 21.98M | 21.98M | 21.98M |
| Gross Profit | 2.15M | -11.09M | -12.70M | -15.63M | -17.36M |
| SG&A Expenses | 28.83M | 28.46M | 27.15M | 24.78M | 24.66M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 75.58M | 71.65M | 66.23M | 65.99M | 68.77M |
| Operating Income | -43.78M | -56.65M | -56.96M | -59.65M | -64.15M |
| Income Before Tax | -58.49M | -56.22M | -54.30M | -58.24M | -62.80M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -58.49 | -56.22 | -54.30 | -58.24 | -62.80 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -58.49M | -56.22M | -54.30M | -58.24M | -62.80M |
| EBIT | -43.78M | -56.65M | -56.96M | -59.65M | -64.15M |
| EBITDA | -42.18M | -55.02M | -55.26M | -58.00M | -62.43M |
| EPS Basic | -0.80 | -0.91 | -0.92 | -1.36 | -1.79 |
| Normalized Basic EPS | -0.50 | -0.57 | -0.57 | -0.83 | -1.10 |
| EPS Diluted | -0.80 | -0.91 | -0.92 | -1.36 | -1.79 |
| Normalized Diluted EPS | -0.50 | -0.57 | -0.57 | -0.83 | -1.10 |
| Average Basic Shares Outstanding | 335.31M | 254.67M | 246.79M | 200.01M | 162.89M |
| Average Diluted Shares Outstanding | 335.31M | 254.67M | 246.79M | 200.01M | 162.89M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |